TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01434706

Intervention type: OTHER
Group type: OTHER
Intervention: Nucleic Acid Amplification Testing
Description: The Gen-Probe Transcription-Mediated Amplification (TMA) technology exponentially amplifies captured HIV-1 and HCV RNA in blood samples. The Gen-Probe system is available in two commercially available FDA approved products; 1) the Procleix assay is a multiplex system that is used to screen the blood supply for HIV and HCV. This assay will allow the simultaneous detection of all known HIV-1 subtypes with sensitivities designed to reduce the window period of false negative results from standard HIV antibody testing (EIA), while maintaining the ability to discriminate positive from negative specimens, even at very low copy numbers (Giachetti, Linnen et al., 2002).
Study: NCT02289924

Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Administration by intravitreal injection
Study: NCT06180967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Syrup
Description: Administered Orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Solution
Description: Administered IV bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered Orally.
Study: NCT04221087

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Sugar water based on same ml dosing of intervention arm drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: 0.6mg/kg/dose - single oral dose administration to intervention arm
Study: NCT03016078

Intervention type: DEVICE
Group type: OTHER
Intervention: Mepilex Border Post-Op Ag
Description: To investigate if there was any skin damage under the dressing from operation day to last visit.
Study: NCT02659267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventions Group
Description: VAMOS is a lifestyle promotion strategy, designed to promote physical activity and healthy eating habits. The intervention is composed by a weekly meeting, 12-week, in group, lasting about 60 min. In each weekly meeting, were discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the VAMOS strategy are based in behavior changes theories. The participants of this group received educational material and, in the middle of the program, they received a pedometer to aid in motivation and in the self-monitoring physical activity.
Study: NCT02678897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxynorm on-demand
Description: We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~1. If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~2. Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxynorm via PCA
Description: We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~1. If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~2. Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5.
Study: NCT01823484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AN 69 ST hemofilter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AN 69 hemofilter
Study: NCT02494869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test
Study: NCT02154568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperpolarized helium MRI of the chest
Description: Using hyperpolarized helium as an inhaled gaseous contrast agent for MRI, we will measure the velocity of inhaled breath in the trachea.
Study: NCT03114605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Study: NCT01750775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shensong Yangxin capsule
Description: ShenSongYangXin Capsule 4 granules t.i.d. by mouth for 8 weeks
Study: NCT02611999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single median price information
Description: Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paired inside/outside price information
Description: Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
Study: NCT02032290

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of Coronary Flow Reserve

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of Coronary Flow Reserve

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor loading

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel loading
Study: NCT04377178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dentin grinder
Description: After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - dentin grinder from the separated root and these particles are incorporated into the extraction socket

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone mill
Description: After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - Bone mill from the separated root and these particles are incorporated into the extraction socket
Study: NCT03473470

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: forced air warming and warmed intravenous fluids
Description: Use of warming system (forced air)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: warmed intravenous fluids
Description: Use of warming system to have warmed intravenous fluids
Study: NCT02354365

Intervention type: DEVICE
Intervention: Transpulmonary Pressure measurement
Description: Transpulmonary pressure measurements are done by placing a catheter (often combined with a feeding tube) into the esophagus of a patient. Intermittently, the esophageal pressure is measured by inflating a small balloon on this catheter. The resulting esophageal pressure is accepted as representing the pleural pressure. The difference between this pressure and the airway pressure is the transpulmonary pressure and PEEP is raised or lowered to make this value zero so that the forces distending the alveoli are just balanced with the natural elasticity of the lung which wants to collapse the alveoli.

Intervention type: DEVICE
Intervention: Transpulmonary Pressure measurement
Description: Transpulmonary pressure measurements are done by placing a catheter (often combined with a feeding tube) into the esophagus of a patient. Intermittently, the esophageal pressure is measured by inflating a small balloon on this catheter. The resulting esophageal pressure is accepted as representing the pleural pressure. The difference between this pressure and the airway pressure is the transpulmonary pressure and PEEP is raised or lowered to make this value zero so that the forces distending the alveoli are just balanced with the natural elasticity of the lung which wants to collapse the alveoli.

Intervention type: DEVICE
Intervention: Transpulmonary Pressure measurement
Description: Transpulmonary pressure measurements are done by placing a catheter (often combined with a feeding tube) into the esophagus of a patient. Intermittently, the esophageal pressure is measured by inflating a small balloon on this catheter. The resulting esophageal pressure is accepted as representing the pleural pressure. The difference between this pressure and the airway pressure is the transpulmonary pressure and PEEP is raised or lowered to make this value zero so that the forces distending the alveoli are just balanced with the natural elasticity of the lung which wants to collapse the alveoli.
Study: NCT03213561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stable and Independent Brain-computer Interfaces for Communication
Description: The participants will perform an MRI head scan, which the investigators will use to construct 3D head models of participants. The investigators will use these modele to reconstruct the activity of brain sources from EEG signals. The participants will then take part in a series of EEG recording sessions. During the initial calibration sessions, the participants will react with real or attempted movements to visual cues. The investigators will use the EEG signals from these sessions to calibrate the text-entry interface used in the validation sessions that follow. During the validation sessions, the participants will control the text-entry interface to write messages using their EEG signals.
Study: NCT03627195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-1349M
Description: DSP-1349M injectable

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo injection
Study: NCT00272961

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBC3711
Description: 10 mg tablets once daily for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBC3711
Description: 50 mg tablet once daily for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBC3711
Description: 100 mg tablet once daily for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBC3711
Description: 200 mg tablet once daily for 10 weeks
Study: NCT00923494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 ml of ropivacaine 0.5%
Description: Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 ml of ropivacaine 0.5%
Description: Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 ml of ropivacaine 0.5%
Description: Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
Study: NCT00796159

Intervention type: DRUG
Intervention: Olmesartan medoxomil
Description: olmesartan medoxomil 20 mg and HCTZ 12.5 mg
Study: NCT04405193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: Eligible patients will be randomised to receive N-acetylcysteine or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT01305317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor
Description: Atorvastatin 20mg daily for 6 months
Study: NCT01779908

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02496871

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Phone Calls
Description: University of Kansas Weight Management Program - Group Phone calls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media
Description: University of Kansas Weight Management Program - Social Media (Facebook)
Study: NCT02334956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain MRI
Study: NCT04896359

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 12.5 grams of ascorbic acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle
Study: NCT03654261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: The intervention is a 1-day Cognitive Behavioural Therapy based workshop.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: The intervention is a 1-day Cognitive Behavioural Therapy based workshop.
Study: NCT01838083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine new formulation HOE901
Description: Pharmaceutical form: solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine new formulation HOE901
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study: NCT00481247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, oral, dasatinib 50-140 mg once daily (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Tablets, oral, imatinib 200-800 mg, QD
Study: NCT02511431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01140035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of continuous insulin infusion for glycemic control in brain dead donors
Description: As per protocol
Study: NCT00321854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole
Study: NCT05214157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: active gas aspiration
Description: sucking remaining Co2 from the peritoneal cavity and local anaesthetic application at port sites
Study: NCT01070394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDX Treatment
Description: 30 mg, 50mg, or 70 mg. Oral capsule, once a day, for 12 weeks.
Study: NCT03125057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemoporfin PDT
Description: Photodynamic therapy is performed using hemoporfin. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemoporfin PDT
Description: Photodynamic therapy is performed using hemoporfin. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
Study: NCT01402583

Intervention type: DRUG
Intervention: PEG IFN/Ribavirin
Description: PEG IFN/Ribavirin
Study: NCT01259401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention Program
Description: Sessions focused on: 1) sleep consolidation and sleep schedule optimization, 2) sleep hygiene education, 3) cognitive therapy, and 4) maintenance of sleep improvements and coping with future bouts of insomnia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education control
Description: During sessions, participants reviewed two educational brochures that focused on changes in sleep with age and sleep hygiene education.
Study: NCT00245622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tovaxin Autologous T cell vaccine
Description: subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
Study: NCT02459639

Intervention type: OTHER
Intervention: Anthroposophic integrative care rehabilitation program
Description: The programme for chronic pain at AIC consists of two phases:~1. A three-week in-patient period. During the first three-week in-patient stay, patients meet regularly with a multi-professional team. Usually, each patient receives two of the following therapies 2-4 times per week: art therapy, massage, physiotherapy, eurhythmy and baths. Nursing care is provided twice daily. Moreover, patients are offered to participate in group activities.~2. Two-three day inpatient follow-up and treatment period closure. The second phase of the treatment programme consists of a 2-3 day inpatient stay, 6 months after closure. During this time, physician, nurse and therapist appointments are made according to individual needs. The patients who have been engaged in group activities are gathered in groups.

Intervention type: OTHER
Intervention: Conventional multi-modal care rehabilitation
Description: The standard approach at Linköping University Hospital admits patients for bio-psycho-social assessment, pharmacological treatment and multimodal rehabilitation (main components: education, intense physical exercise, cognitive behavioural therapy and workplace interventions) for a 6 week intensive phase period (75%) followed by 4 weeks (25%). Here a number of professional disciplines collaborate and form a team of professionals focused on individual patient needs The multimodal rehabilitation outpatient program delivered by this team has the following aims: 1) reduce pain and psychological burden, 2) improve work capacity and decrease sick-leave and 3) increase perceived health and quality of life. These general aims are combined with the aims of the patient in a plan of rehabilitation.
Study: NCT05826106

Intervention type: PROCEDURE
Intervention: R anastomosis
Description: Modifying the surgical technique of totally laparoscopic Billroth-II reconstruction with Braun anastomosis and to name it as the R anastomosis.
Study: NCT02145403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.~Dose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.
Study: NCT04354337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Innovations for Preschoolers with Arthritis (SIPA)
Description: The SIPA intervention is interactive and personalized. Every week, parent will receive an email sent automatically through the system with instructions for this week's activity, designed to take about 30 minutes to complete. The SIPA weekly modules will begin with a learning module, then direct participants through goal setting, anticipated barriers, and problem solving. The intervention site will include fillable responses to queries, instructions, and assignments. Tasks for parents and their young children will use multimedia elements to enhance delivery of information, such as links to videos and pictures targeting self-efficacy, motivation, and patient activation. Submissions and progress will be monitored by the study team, who will send email, call or text with reminders (whichever the family prefers) and answer questions as needed, review progress, and help problem solve any technology issues or barriers to implementing skills.
Study: NCT00528879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks
Study: NCT00528879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Open-label metformin administered as ≥1500 mg per day for up to 102 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Open-label metformin administered as ≥1500 mg per day for up to 102 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Open-label metformin administered as ≥1500 mg per day for up to 102 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Open-label metformin administered as ≥1500 mg per day for up to 102 weeks
Study: NCT01880099

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo compared to 8mg of Galantamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine 8mg
Description: 8mg of galantamine compared to placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine 16mg
Description: 16mg of galantamine compared to placebo
Study: NCT01073683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laryngoscopy
Description: Treatment of advanced larynx cancer with induction TPF, in order to decide between chemoradiation and laryngeal preservation surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere (Docetaxel), Cisplatin, 5FU
Description: Taxotere 75 mg/m2 D1, Cisplatin 75 mg/m2 D1, 5FU 750 mg/m2 D1-4
Study: NCT01261325

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs with market authorization available per country

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs with market authorization available per country

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiepileptic drugs with market authorization available per country